Modern Chinese Medicine Group Co., Ltd.
Research Modern Chinese Medicine Group Co., Ltd. (1643.HK) on Bullrun: market cap HKD 262.80M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker1643.HK
- ExchangeHK
- CountryChina
- SectorHealthcare
- IndustryDrug Manufacturers - General
- CurrencyHKD
- Market capHKD 262.80M
- Financial periodFY2025
- RevenueCNY 145.17M
- Revenue growth-32.2%
- Net income-CNY 13.56M
- Free cash flow-CNY 17.73M
- Gross margin16.2%
Valuation Snapshot
latest market cap is HKD 262.80M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CNY 145.17M | -CNY 13.56M | -CNY 17.73M | 16.2% | n/a | CNY 229.71M | CNY 69.00K | CNY 497.99M |
| FY2024 | CNY 214.07M | CNY 9.67M | -CNY 55.32M | 25.8% | 0.02 | CNY 229.67M | CNY 135.00K | CNY 484.23M |
| FY2023 | CNY 344.08M | CNY 48.80M | CNY 3.38M | 30.3% | 0.08 | CNY 286.27M | CNY 72.00K | CNY 472.89M |
| FY2022 | CNY 399.66M | CNY 87.83M | CNY 114.06M | 42.7% | 0.15 | CNY 282.26M | CNY 393.00K | CNY 422.93M |
| FY2021 | n/a | n/a | n/a | n/a | 0.14 | n/a | n/a | n/a |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | HKD 262.80M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 HKD.
| Year | Dividends/share |
|---|---|
| FY2022 | 0.02 CNY |
About Modern Chinese Medicine Group Co., Ltd.
Modern Chinese Medicine Group Co., Ltd., an investment holding company, engages in the production and sale of proprietary Chinese medicines in the People's Republic of China.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Modern Chinese Medicine Group Co., Ltd.'s market cap?
Modern Chinese Medicine Group Co., Ltd.'s market capitalization is HKD 262.80M.
What does Modern Chinese Medicine Group Co., Ltd. do?
Modern Chinese Medicine Group Co., Ltd., an investment holding company, engages in the production and sale of proprietary Chinese medicines in the People's Republic of China. It provides vigour and vitality supplement, circulation enhancement pills, cardiotonic enhancement capsules, kidney invigoration pill, heart wellness capsules, menstrual discomfort relief, liver detox tablets, additional ingredient Huoxiang Zheng Qi pill, liver-dispersing and stomach regulating pills, and fever- removing and detoxification pills.